Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 1.23
CORT's Cash to Debt is ranked lower than
76% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. CORT: 1.23 )
Ranked among companies with meaningful Cash to Debt only.
CORT' s Cash to Debt Range Over the Past 10 Years
Min: 0.72  Med: 1190.67 Max: No Debt
Current: 1.23
Equity to Asset 0.28
CORT's Equity to Asset is ranked lower than
84% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CORT: 0.28 )
Ranked among companies with meaningful Equity to Asset only.
CORT' s Equity to Asset Range Over the Past 10 Years
Min: -0.1  Med: 0.62 Max: 0.89
Current: 0.28
-0.1
0.89
F-Score: 5
Z-Score: -1.75
M-Score: -2.41
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -18.43
CORT's Operating margin (%) is ranked higher than
62% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. CORT: -18.43 )
Ranked among companies with meaningful Operating margin (%) only.
CORT' s Operating margin (%) Range Over the Past 10 Years
Min: -69827.59  Med: -2540.46 Max: -104.02
Current: -18.43
-69827.59
-104.02
Net-margin (%) -25.40
CORT's Net-margin (%) is ranked higher than
59% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. CORT: -25.40 )
Ranked among companies with meaningful Net-margin (%) only.
CORT' s Net-margin (%) Range Over the Past 10 Years
Min: -69537.93  Med: -2401.04 Max: -118.2
Current: -25.4
-69537.93
-118.2
ROE (%) -182.41
CORT's ROE (%) is ranked lower than
90% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. CORT: -182.41 )
Ranked among companies with meaningful ROE (%) only.
CORT' s ROE (%) Range Over the Past 10 Years
Min: -356.04  Med: -113.30 Max: -55.4
Current: -182.41
-356.04
-55.4
ROA (%) -25.98
CORT's ROA (%) is ranked higher than
51% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. CORT: -25.98 )
Ranked among companies with meaningful ROA (%) only.
CORT' s ROA (%) Range Over the Past 10 Years
Min: -124.18  Med: -87.40 Max: -51.57
Current: -25.98
-124.18
-51.57
ROC (Joel Greenblatt) (%) -347.50
CORT's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. CORT: -347.50 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CORT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -370585.71  Med: -69112.91 Max: -2412.14
Current: -347.5
-370585.71
-2412.14
EBITDA Growth (3Y)(%) -11.50
CORT's EBITDA Growth (3Y)(%) is ranked lower than
61% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. CORT: -11.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CORT' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -11.50 Max: 2.6
Current: -11.5
0
2.6
EPS Growth (3Y)(%) -7.10
CORT's EPS Growth (3Y)(%) is ranked lower than
54% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. CORT: -7.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CORT' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -31.4  Med: -7.10 Max: 6.7
Current: -7.1
-31.4
6.7
» CORT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

CORT Guru Trades in Q1 2015

Jim Simons 55,400 sh (New)
» More
Q2 2015

CORT Guru Trades in Q2 2015

First Eagle Investment 200,000 sh (New)
Jim Simons 501,614 sh (+805.44%)
» More
Q3 2015

CORT Guru Trades in Q3 2015

Paul Tudor Jones 21,279 sh (New)
Joel Greenblatt 17,221 sh (New)
David Swensen 22,334 sh (New)
First Eagle Investment 300,000 sh (+50.00%)
Jim Simons 452,200 sh (-9.85%)
» More
Q4 2015

CORT Guru Trades in Q4 2015

Jim Simons 460,400 sh (+1.81%)
First Eagle Investment 300,000 sh (unchged)
David Swensen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CORT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 32.16
CORT's P/B is ranked lower than
99.99% of the 1128 Companies
in the Global Biotechnology industry.

( Industry Median: 2.66 vs. CORT: 32.16 )
Ranked among companies with meaningful P/B only.
CORT' s P/B Range Over the Past 10 Years
Min: 1.26  Med: 5.47 Max: 97.67
Current: 32.16
1.26
97.67
P/S 9.15
CORT's P/S is ranked higher than
53% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 9.03 vs. CORT: 9.15 )
Ranked among companies with meaningful P/S only.
CORT' s P/S Range Over the Past 10 Years
Min: 8.07  Med: 140.00 Max: 615
Current: 9.15
8.07
615
Current Ratio 2.41
CORT's Current Ratio is ranked lower than
69% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. CORT: 2.41 )
Ranked among companies with meaningful Current Ratio only.
CORT' s Current Ratio Range Over the Past 10 Years
Min: 2.22  Med: 7.89 Max: 37.77
Current: 2.41
2.22
37.77
Quick Ratio 2.32
CORT's Quick Ratio is ranked lower than
66% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. CORT: 2.32 )
Ranked among companies with meaningful Quick Ratio only.
CORT' s Quick Ratio Range Over the Past 10 Years
Min: 2.14  Med: 7.89 Max: 37.77
Current: 2.32
2.14
37.77
Days Inventory 386.93
CORT's Days Inventory is ranked lower than
92% of the 416 Companies
in the Global Biotechnology industry.

( Industry Median: 126.53 vs. CORT: 386.93 )
Ranked among companies with meaningful Days Inventory only.
CORT' s Days Inventory Range Over the Past 10 Years
Min: 476.53  Med: 1710.69 Max: 2487.36
Current: 386.93
476.53
2487.36
Days Sales Outstanding 48.95
CORT's Days Sales Outstanding is ranked higher than
66% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. CORT: 48.95 )
Ranked among companies with meaningful Days Sales Outstanding only.
CORT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.83  Med: 50.33 Max: 61.48
Current: 48.95
45.83
61.48
Days Payable 506.06
CORT's Days Payable is ranked higher than
95% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 57.67 vs. CORT: 506.06 )
Ranked among companies with meaningful Days Payable only.
CORT' s Days Payable Range Over the Past 10 Years
Min: 780.49  Med: 6077.38 Max: 15257.8
Current: 506.06
780.49
15257.8

Valuation & Return

vs
industry
vs
history
Price/Net Cash 386.00
CORT's Price/Net Cash is ranked lower than
99% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: 5.67 vs. CORT: 386.00 )
Ranked among companies with meaningful Price/Net Cash only.
CORT' s Price/Net Cash Range Over the Past 10 Years
Min: 2.5  Med: 5.72 Max: 376
Current: 386
2.5
376
Price/Net Current Asset Value 42.89
CORT's Price/Net Current Asset Value is ranked lower than
92% of the 883 Companies
in the Global Biotechnology industry.

( Industry Median: 5.05 vs. CORT: 42.89 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CORT' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.43  Med: 5.96 Max: 93.33
Current: 42.89
2.43
93.33
Price/Tangible Book 32.17
CORT's Price/Tangible Book is ranked lower than
95% of the 1034 Companies
in the Global Biotechnology industry.

( Industry Median: 9.50 vs. CORT: 32.17 )
Ranked among companies with meaningful Price/Tangible Book only.
CORT' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.31  Med: 5.89 Max: 93.33
Current: 32.17
2.31
93.33
Price/Median PS Value 0.07
CORT's Price/Median PS Value is ranked higher than
98% of the 846 Companies
in the Global Biotechnology industry.

( Industry Median: 0.87 vs. CORT: 0.07 )
Ranked among companies with meaningful Price/Median PS Value only.
CORT' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.06  Med: 0.32 Max: 3.74
Current: 0.07
0.06
3.74
Earnings Yield (Greenblatt) (%) -2.05
CORT's Earnings Yield (Greenblatt) (%) is ranked higher than
63% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. CORT: -2.05 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CORT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -11  Med: 3588.90 Max: 3588.9
Current: -2.05
-11
3588.9

More Statistics

Revenue(Mil) $44
EPS $ -0.12
Beta1.46
Short Percentage of Float9.54%
52-Week Range $3.02 - 7.67
Shares Outstanding(Mil)108.78

Analyst Estimate

Dec15
Revenue(Mil)
EPS($) -0.22
EPS without NRI($) -0.22

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:HTD.Germany,
Corcept Therapeutics Inc was incorporated in the State of Delaware on May 13, 1998. The Company is a pharmaceutical Company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric and oncologic disorders. Company focuses on disorders associated with the steroid hormone cortisol. The company focuses on commercializing Korlym 300 mg Tablet, a once-daily oral medication for treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushings syndrome, who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It is also conducting a Phase III clinical study for mifepristone, the active ingredient in Korlym, for the treatment of psychotic depression; and developing CORT 108297, a novel glucocorticoid receptor II antagonist in Phase 1b/2a clinical trial. The Company has research and development agreement with Argenta Discovery Limited; Sygnature Discovery Limited; ICON Clinical Research, L.P.; and MedAvante, Inc. as well as has a patent license from Stanford University for developing mifepristone.
» More Articles for CORT

Headlines

Articles On GuruFocus.com
Two Stocks for the Value Investor and GAARP Enthusiast Jun 07 2014 
Corcept Therapeutics Inc. Reports Operating Results (10-K/A) Aug 19 2010 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) Aug 16 2010 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) Nov 12 2009 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) Aug 11 2009 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) May 13 2009 

More From Other Websites
Genocea Doses Patients in Phase IIb Study on GEN-003 Feb 01 2016
Corcept Reports Preliminary Q4 Earnings, Revenues in Line Jan 29 2016
Edited Transcript of CORT earnings conference call or presentation 28-Jan-16 10:00pm GMT Jan 29 2016
Corcept Therapeutics Announces Preliminary Fourth Quarter and Full Year 2015 Summary Financial... Jan 28 2016
CORCEPT THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure Jan 28 2016
Corcept Therapeutics Announces Preliminary Fourth Quarter and Full Year 2015 Summary Financial... Jan 28 2016
Preliminary Q4 2015 Corcept Therapeutics Inc Earnings Release - After Market Close Jan 28 2016
Corcept Therapeutics to Announce Preliminary 2015 Financial Results, Provide 2016 Revenue Guidance... Jan 22 2016
Corcept Therapeutics to Announce Preliminary 2015 Financial Results, Provide 2016 Revenue Guidance... Jan 21 2016
Intellipharmaceutics Up on Positive Rexista Oxycodone Data Jan 15 2016
Corcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : January 5, 2016 Jan 05 2016
Why Are These Stocks Advancing on Tuesday? Dec 29 2015
Ohr Pharmaceutical (OHRP) Worth Watching: Stock Up 10.5% Dec 22 2015
Corcept Therapeutics, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 21 2015
Technical Report on Biotechnology Stocks -- Arena Pharma, Cara Therapeutics, Corcept Therapeutics,... Dec 21 2015
Corcept Releases Initial Data on Korlym/Halaven Combination Dec 15 2015
Perception, Opportunity in Volatility - Featured Research on Corcept Therapeutics, Pioneer Energy... Dec 15 2015
Corcept Therapeutics Incorporated (CORT): Are Hedge Funds Right About This Stock? Dec 14 2015
Corcept Therapeutics Announces Initial Efficacy Results in Phase 1/2 Trial of Mifepristone in... Dec 14 2015
Corcept Therapeutics Announces Initial Efficacy Results in Phase 1/2 Trial of Mifepristone in... Dec 14 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK